Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in adolescents with moderate to severe plaque psoriasis
NL-OMON35122Phase 3Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in plaque psoriasis and psoriatic arthritis (PsA) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Physician's Global Assessment response at Week 12. Planned start Apr 2010; status: withdrawn.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON35122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35122.